Alpha Interferon in AIDS-Related Progressive Multifocal Leukoencephalopathy.
Alpha Interferon in AIDS-Related Progressive Multifocal Leukoencephalopathy.
复制标题
DOI：
10.1300/j128v01n04_08
复制
发表时间：
1996-01-01
期刊：
影响因子：
--
通讯作者：
Sabin, T D
中科院分区：
文献类型：
--
作者：
Counihan, T;Venna, N;Sabin, T D
目的：确定重组干扰素α治疗获得性免疫缺陷综合征（AIDS）伴进行性多灶性白质脑病的疗效。设计：开放标签，非对照研究。地点：马萨诸塞州波士顿市医院神经内科和临床艾滋病项目。患者：连续4例经病理证实为进行性多灶性脑白质病的艾滋病患者。干预：每位患者接受4-12周的α干扰素治疗，每日5-10万单位，皮下给药。此外，四人中有两人在同一时期口服阿昔洛韦2400毫克/天。结果：所有患者均无临床反应；平均生存期为14周。没有发现治疗的不良反应。结论：尽管有轶事证据表明α干扰素对非艾滋病患者进行性多灶性脑白质病变有效，但这些患者的经验表明，该药物对艾滋病相关PML没有益处。
OBJECTIVE: To determine the efficacy of recombinant interferon alpha in the treatment of progressive multifocal leukoencephalopathy associated with the acquired immunodeficiency syndrome (AIDS).DESIGN: Open label, uncontrolled study.SETTING: Neurological unit and clinical AIDS program, Boston City Hospital, Boston, MA.PATIENTS: Four consecutive AIDS patients with pathologically confirmed progressive multifocal leukoencephalopathy.INTERVENTION: Each patient received alpha interferon for 4-12 weeks in a dose of 5-10 million units daily, administered subcutaneously. In addition, two of the four were taking acyclovir 2400 mg/day orally over the same period.RESULTS: None of the patients showed any clinical response to the therapy; the mean survival was 14 weeks. No adverse effects of the treatment were encountered.CONCLUSIONS: Despite anecdotal evidence that alpha interferon is effective in the treatment of progressive multifocal leukoencephalo pathy in non-AIDS patients, the experience of these patients suggests that the drug is of no benefit in AIDS-related PML.